Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina  by Rupprecht, Hans-Jürgen et al.
JACC Vol. 26, No. 7 1637 
December 1995:1637-42 
MYOCARDIAL ISCHEMIA 
Recombinant Hirudin (HBW 023) Prevents Troponin T Release After 
Coronary Angioplasty in Patients With Unstable Angina 
HANS-JURGEN RUPPRECHT, MD, WOLFRAM TERRES, MD,* CEM OZBEK, MD,? 
MATTHIAS LUZ, MD,:I: ANDREAS JESSEL, MD,:I: GERD HAFNER, MD, 
J I ]RGEN VOM DAHL, MD,§ ECKHARD P. KROMER, MD,II 
WINFRIED PRELLWITZ, MD, J I ]RGEN MEYER, MD 
Mainz, Hamburg, Homburg, Marburg, Aachen and Regensburg, German), 
Objectives. This study was performed to evaluate the efficacy of 
peri-interventional treatment with recombinant hirudin (r- 
hirudin [HBW 023]) compared with heparin in the prevention of 
troponin T release in patients with unstable angina. 
Background. Percntaneous transluminal coronary angioplasty 
in patients with unstable angina is associated with a high risk of 
acute thrombotic omplications. 
Methods. Serial troponin T measurements were performed in 
61 patients with unstable angina during the 48-h observation 
period after coronary angioplasty of the ischemia.related lesion. 
Patients were randomly assigned to peri-interventional intrave- 
nous treatment with either r-hirudin (dosage group I: 0.3.mg/kg 
body weight bolus, 0.12 mg/kg per h for 24 h; dosage group II: 
0.5.mg/kg bolus, 0.24 mg/kg per h for 24 h) or heparin (150.IU/kg 
bolus, 20 IU/kg per h for 24 h). All patients received acetylsalicylic 
acid before coronary angiography. After 24 h, patients received a 
constant low dose infusion of either hirudin (0.04 mg/kg per h) or 
heparin (7 IU/kg per h) for another 24 h. The power of the study 
to detect a decrease in abnormal troponin T levels from 60% 
(heparin group) to 20% (combined r-hirudin groups) was 88%. 
Results. Serial troponin T measurements revealed two peaks 
within the 48 h after coronary angioplasty in the heparin but not 
the hirudin groups. An elevated serum troponin T concentration 
(>0.2 ng/ml) within 48 h of coronary angioplasty was found in 9 
(24%) of 38 patients in the hirudin groups (5 [25%] of 20 in 
dosage group I; 4 [22%] of 18 in dosage group lI) compared with 
11 (58%) of 19 in the heparin group (p = 0.01). We observed major 
cardiac events (death, myocardial infarction, abrupt vessel clo. 
sure) in 1 (4.8%) of 21 patients in dosage group I, 1 (5.3%) of 19 
in dosage group II and 3 (14.3%) of 21 in the heparin group (p = 
0.33). 
Conclusions. In this pilot trial, hirudin appears to be superior 
to heparin in preventing troponin T release after coronary angio- 
plasty. 
(J Am CoU Cardiol 1995;26:1637-42) 
Plaque rupture and subsequent thrombus formation have been 
shown (1-6) to play a fundamental role in the pathogenesis of 
unstable angina. In this subgroup of patients, percutaneous 
transluminal coronary angioplasty is associated with a marked 
risk of acute thrombotic complications a a result of extension 
of the underlying plaque rupture and further endothelial injury 
with augmented platelet activity, increased clotting activity and 
attendant spasm (7-14). The risk of acute vessel occlusion in 
these patients i  thought to depend primarily on the extent of 
dissection and thrombin generation at the site of the lesion. 
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Thrombin ot only plays a key role within the dotting system, 
but is also the most potent and physiologically important 
activator of platelets. 
The incidence of acute complications has been reduced by 
the use of heparin and acetylsalicylic a id (aspirin) before, 
during and after coronary angioplasty (15-17). However, there 
is strong evidence (18) that heparin and aspirin may not 
completely prevent coagulation activation during coronary 
angioplasty. Hirudin, a highly specific and direct inhibitor of 
thrombin, has been shown to be highly effective in preventing 
arterial thrombosis in animal (19-23) and human studies 
(24-26). It has therefore been postulated that hirudin might 
counteract oagulation activation and reduce ischemic events 
in patients undergoing coronary angioplasty for unstable an- 
gina. Because of its high sensitivity and specificity, troponin T 
has been used to detect myocardial cell injury (27). 
Methods  
Patients. Patients with a clinical diagnosis of unstable an- 
gina pectoris were eligible for inclusion in this multicenter trial, 
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provided that the following criteria were met: 1) angina t rest, 
recent onset angina (<-4 weeks), postinfarction angina (<-4 
weeks) or prolonged (->10 min) or recurrent angina (at least 
two episodes lasting ->5 rain in any 1 day); 2) last attack of 
chest pain within the preceding 48 h; 3) at least one stenosis 
with a diameter eduction of at least 70% in any major 
coronary artery (right, left circumflex or left anterior descend- 
ing or any side branch >2 mm in diameter) that was consid- 
ered to be responsible for clinical symptoms and suitable for 
coronary angioplasty. Reasons for exclusion were >75 years 
old, body weight > 100 kg, known abuse of alcohol or drugs and 
known hypersensitivity to contrast media or trial drugs, as well 
as acute myocardial infarction, thrombolytic therapy within the 
preceding week, hemodynamic instability, bleeding disorders 
or conditions predisposing to bleeding, history of intracranial 
aneurysm or stroke, uncontrolled hypertension (>180/ 
100 mm Hg), serum creatinine l vels >133 v, mol/liter or other 
relevant and serious diseases. Ethical approval was obtained 
before start of the study, and informed written consent was 
obtained from all patients. 
Study protocol. The study was designed as an open, 
heparin-controlled, randomized, multicenter t ial. Two doses 
of recombinant hirudin (r-hirudin) were sequentially investi- 
gated. Within each dose group, patients were randomized to 
the two treatments (heparin or r-hirudin), with an overall ratio 
of 1:2. 
In patients who received continuous intravenous heparin, 
the infusion was stopped before arterial puncture. Patients 
without premedication with aspirin received 500 mg of aspirin 
before coronary angiography. All patients were given an 
intracoronary bolus injection of 0.1 to 0,3 mg of nitroglycerin 
before coronary angiography. Immediately before coronary 
angioplasty, an intravenous bolus of either -hirudin or heparin 
was given according to randomization. Thereafter, a constant 
infusion of r-hirudin or heparin was started and continued for 
24 h. 
After 22 to 26 h, repeat coronary angiography was per- 
formed to document the early result of coronary angioplasty. 
Two to three hours after the end of the control angiography, 
the arterial sheath was removed. A low dose infusion of the 
trial medication (r-hirudin or heparin) was subsequently in- 
stilled for another 24 h to prevent hromboembolism during 
the period of bed rest; aspirin was continued ina dosage of 10() 
to 300 mg/day. 
Study medication. Recombinant hirudin. Recombinant 
hirudin (HBW 023, Behringwerke AG, Marburg, Germany) 
was administered intravenously intwo different dose regimens: 
DOSE GROUP I = 0.3-mg/kg body weight bolus, followed by a 
constant 24-h infusion of 0.12 mg/kg per h. The goal was 
twofold to fourfold prolongation of the reference activated 
partial thromboplastin me. DOSE GROUP II = 0.5-mg/kg bolus, 
followed by a constant 24-h infusion of 0.24 mg/kg per h. The 
aim was to attain a twofold to fivefold prolongation of the 
reference activated partial thromboplastin time. 
An additional bolus of either 0.3 or 0.5 mg/kg (depending 
on the dose group) was given when the activated partial 
Table l. Patient and Lesion Characteristics 
r-Hirudin 
Dosage Dosage Heparin 
Group I Group II Group 
(n = 21) (n : 19) (n = 21) 
Male/female 18/3 15/4 14/7 
Age (yr) 58 ,+ 8 61 _+ 9 60 _+ 10 
Time from onset of last 23.0 ,+ 14.0 22.7 _+ 13.2 20.5 ,+ 14.3 
episode of chest pain to 
start of treatment (h) 
Time from start of 21.7 ,+ 6.8 23.6 _+ 4.6 21.6 _+ 7.1 
treatment to change to 
low dose infusion (h) 
No. of stenoses treated 23 25 22 
Multivessel disease 11 7 5 
Location of stenosis 
LAD 14 13 17 
RCA 3 4 3 
LCx 6 8 2 
Diameter stcnosis before 78.7 ,+ 7.8 79.6 _+ 9.7 80.9 -- 9.8 
coronary, angioplasty 
Diameter stenosis after 33.1 ,+ 9.3 34.2 ,+ 10.7 35.1 ,+ 9.4 
coronary angioplasty 
Acute angiographic success 20/'20 19/19 18/20 
Diameter stenosis after 24 h 39.0 + 11.6 39.1 _+ 13.0 41.6 _+ 8.8 
Thrombus before coronary I0 10 10 
angioplasty 
Yhrombus after 24 h 9 9 8 
Data presented are mean value -+ SD or number of patients, unless 
otherwise indicated. LAD - left anterior descending coronary artery; LCx = left 
circumflex coronary artery; PTCA = percutaneous transluminal coronary angio- 
plasty; RCA - right coronary artery; r-hirudin = recombinant hirudin. 
thromboplastin time failed to reach the target range. If the 
activated partial thromboplastin me exceeded the upper limit 
of the target range, the infusion was interrupted for 2 h. After 
24 h (end of the trial infusion), patients received a constant 
24-h infusion of 0.04 mg/kg per h (both dose groups). 
Heparin group. Patients received an intravenous bolus of 
150 IU/kg of unfractionated heparin (Liquemin, Hoffmann 
LaRoche, Basle, Switzerland), followed by a constant 24-h 
intravenous infusion of 20 IU/kg per h. The activated partial 
thromboplastin time was adjusted to a twofold to fourfold 
prolongation ofthe reference value. After 24 b (end of the trial 
infusion), patients received a constant 24-h infusion of 7 IU/ 
kg per h. 
For patients who did not receive heparin before interven- 
tion, the patient's own baseline activated partial thromboplas- 
tin time was taken as the reference value in all treatment 
groups. For patients who were receiving heparin, the median 
activated partial thromboplastin me of the normal range was 
used. 
Coronary angiography and coronary angioplasty. Coro- 
nary angiography and coronary angioplasty were performed 
using routine techniques through the femoral route. The 
cineangiograms were evaluated at the central core angio- 
graphic laboratory of the Medical Clinic II of the University of 
Mainz. All angiograms were stored on 35-ram cinefilm at 25 to 
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50 frames/s. After optical magnification, automatic gain and 
offset adjustment and digitization (512 x 512 pixels, eight bits), 
visual border ecognition and tracing of the single worst view 
projection (i.e., that showing the most representative stenosis 
image) were performed. The traced vessel borders were stored, 
and the lesion variables and reference diameters were auto- 
matically computed. 
lntracoronary thrombus was defined as an intraluminal 
filling defect surrounded on at least hree sides with or without 
staining. Angiographic success was defined as diameter stenosis 
<50% immediately after coronary angioplasty. 
Clinical events. Clinical events were documented until 
hospital discharge and were defined as follows: death, acute 
myocardial infarction, need for emergency coronary angio- 
plasty or bypass graft surgery, recurrent chest pain and major 
and minor bleeding. Major bleeding was defined as either overt 
bleeding requiring transfusion or surgical intervention or in- 
tracranial bleeding. Myocardial infarction was defined as a 
more than twofold increase in creatine kinase (CK) levels 
above the upper limit of the reference site. Recurrent angina 
was defined as typical anginal chest pain at rest. Electrocar- 
diograms were required on admission and after 24 and 48 h. 
Laboratory investigations. Laboratory studies were per- 
formed to determine coagulation variables, including activated 
partial thromboplastin time as well as variables of myocardial 
cell necrosis (CK, troponin T). The activated partial thrombo- 
plastin time and variables of myocardial cell necrosis were 
measured before and directly after coronary angioplasty, as 
well as after 4, 8, 16, 24, 27 and 48 h. Other laboratory variables 
were measured on admission and after 24 and 48 h. Troponin 
T levels were assessed by enzyme-linked immunosorbent assay 
(27). 
Statistical analysis. Graphical and descriptive methods 
were used to summarize the data and to present he results of 
the study. Quantitative data are expressed as mean value _ SD 
or as median (25%/75% percentiles). Statistical comparisons 
were based on the Fisher exact est (two-sided, alpha 5%) for 
the combined r-hirudin treatment groups versus the heparin 
group. The power of the study to detect adecrease inabnormal 
troponin T levels from 60% (heparin group) to 20% (com- 
bined r-hirudin groups) was 88%. The study was not designed 
to detect meaningful differences with regard to clinical out- 
come. A p value <0.05 was considered to indicate a significant 
difference. Data were stored on an HP 3000 data base. Statisti- 
cal analyses were performed by means of PC-SAS software, 
version 6.04. 
Results 
Baseline patient characteristics are summarized in Table 1. 
Altogether, there were no significant differences among the 
three treatment groups. It was possible to perform safety 
analyses for all 61 patients and efficacy analyses for 59 (with 
respect to angiographic outcome). One patient (dosage group I) 
was excluded from the efficacy analysis because coronary 
angioplasty was not performed after randomization owing to 
Table 2. Adverse Events 
r-Hirudin 
Dosage Dosage Heparin 
Group I Group II Group p 
(n = 21) (n = 19) (n = 21) Value 
Adverse cardiac events 
Serious 
Death 1 (4.8%)* 1 (4.8%) 
Myocardial infarction 1 (4.8%) 1 (5.3%) 
Acute coronary occlusion 1 (4.8%) 3 (14.3%) 
PTCA/stent 1 (4.8%) 2 (9.5%) 
CABG 1 (4.8%) 
Total pts affected 1 (4.8%) 1 (5.3%) 3 (14.3%) 0.33 
Minor 
Recurrent chest pain 2 (10.5%) 
ECG ST segment change 3(14.3%) 2(10.5%) 3(14.3%) 
Total pts affected 3(14.3%) 2(10.5%) 3(14.3%) 1.0 
Bleeding complications 
Major 1 (5.3%) 
Minor 2 (9.5%) 3 (14.3%) 
Total pts affected 2 (9.5%) 1 (5.3%) 3 (14.3%) 0.41 
*Sudden death on day 11 due to reinfarction. Data presented are number 
(%) of patients (pts). CABG = coronary artery, bypass graft surgery; ECG = 
electrocardiographic; other abbreviations a in Table 1. 
the absence of a significant lesion; a coronary spasm had to be 
considered. Another patient (heparin group) had to be ex- 
cluded because informed consent was withdrawn 5 h after 
commencement of treatment with the drugs under investiga- 
tion. 
Angiographic results. The number of attempted lesions, 
lesion location, severity of the lesions and other lesion vari- 
ables were comparable in the treatment groups. Angiographic 
success was achieved in all patients in dosage groups I and II 
and in 18 of 20 patients in the heparin group (Table 1). No 
significant differences were found in the preangioplasty and 
postangioplasty incidence of intracoronary thrombus forma- 
tion (Table 1). 
Serious adverse cardiac events. In dosage group I, one 
patient had an abrupt coronary occlusion during coronary 
angioplasty, with subsequent transmural myocardial necrosis 
(Table 2). On day 11, the patient died suddenly after reinfarc- 
tion. In dosage group II, one patient experienced a myocardial 
infarction on day 4. In the heparin group, one patient experi- 
enced an abrupt coronary occlusion during coronary angio- 
plasty that necessitated mergency bypass graft surgery. This 
patient died on day 2 of extensive infarction with refractory 
cardiogenic shock. Two patients experienced abrupt coronary 
occlusion after coronary angioplasty that was successfully 
treated by stent implantation. Altogether, cardiac events were 
more frequent in the heparin group (three patients, 14.3%) 
than in the hirudin groups (one patient each in dosage group 
I [4.8%] and dosage group II [5.3%]). However, this difference 
was not statistically significant (p = 0.33). 
Minor adverse cardiac events. Recurrent chest pain was 
observed in two patients (10.5%) in dosage group II (Table 2). 
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Figure 1. Troponin T concentrations ( g/ml) 
(medians [circles] with 25%/75% percentiles 
[vertical lines]). Upper limit 0.2 ng/ml. 
Deterioration of the ST-T wave within 48 h of coronary 
angioplasty was observed in three patients (14.3%) in dosage 
group I, two (10.5%) in dosage group II and three (14.3%) in 
the heparin group (p = 1.0). 
Bleeding complications. One major bleeding complication 
related to the catheter insertion site occurred in dosage group 
II and prompted transfusion of 2 U of blood (Table 2). There 
were two cases of minor bleeding at the puncture site in dosage 
group I and three in the heparin group (p = 0.41). 
Markers of myocardial cell necrosis. We observed a sig- 
nificant increase in troponin T levels at 8 h after commence- 
ment of drug infusion in the heparin group (Fig. 1). Another 
peak was seen 27 h after the start of drug infusion (3 h after 
switching from the high to the low dose regimen). There was 
no comparable increase in troponin T levels in either of the 
hirudin groups (Fig. 1). A serum troponin T concentration 
>0.2 ng/ml was measured within 48 h of coronary angioplasty 
in 5 (25%) of 20 patients in dosage group I and 4 (22.2%) of 
18 in dosage group II. Altogether, 9 (23.7%) of 38 patients in 
the hirudin groups had elevated troponin T levels compared 
with 11 (57.9%) of 19 patients in the heparin group (p = 0.01). 
There was no peak and no significant difference with regard to 
CK enzyme activity between the treatment groups. A patho- 
logic increase in CK enzyme activity was observed in only one 
patient in each treatment group. 
Coagulation variables. Median prolongation of the acti- 
vated partial thromboplastin time compared with baseline was 
found to be 1.9-fold (range 0.9 to 4.7) in dosage group I, 
2.3-fold (range 1.6 to 3.6) in dosage group II and 3.0-fold 
(range 1.0 to 3.9) in the heparin group at 24 h. 
Discuss ion  
Role of hirudin. Angioplasty in unstable angina is subject 
to a higher rate of complications than in stable angina, mainly 
because of thrombin generation at the site of the lesion. 
Hirudin, a specific inhibitor of thrombin, has been shown in 
previous tudies (19-26) to be highly effective in preventing 
arterial thrombosis. Hirudin is a direct thrombin inhibitor and, 
in contrast o heparin, does not require antithrombin III as a 
cofactor. It is active against clot-bound thrombin, whereas 
heparin predominantly inhibits soluble thrombin (28). More- 
over, heparin-induced thrombin inhibition can be counteracted 
by platelet factor 4 and fibronectin (21,22,24,29-31). Hirudin is 
also an effective inhibitor of thrombin-induced platelet activa- 
tion (32-34), an observation that suggests that hirudin might 
be superior to heparin in preventing thrombotic complications 
in patients with unstable angina undergoing coronary angio- 
plasty. 
Serious adverse events. Because of the small sample size, 
the present study did not have the power to show significant 
differences in clinical outcome, although there was a trend 
toward more serious adverse cardiac events in the heparin 
group. In a recent multicenter t ial (31), hirulog was compared 
with heparin in coronary angioplasty; there was a trend toward 
fewer abrupt vessel occlusions in the hirulog-treated group. 
Recent trials (35,36) indicate that hirudin reduces the inci- 
dence of major adverse cardiac events after angioplasty in 
patients with unstable angina. 
Troponin T release. Previous studies have shown (27,37) 
troponin T to have a high sensitivity and specificity for 
myocardial cell injury. For example, Hammet al. (37) reported 
elevated troponin T levels in patients with acute angina at rest. 
Only a minority of these patients had elevated CK-MB activity. 
Recently Talasz et al. (38) reported a significant increase in 
troponin T levels in patients with side branch occlusion after 
coronary angioplasty. In coronary angioplasty without compli- 
cations, there was no significant increase in plasma concentra- 
tions of troponin T (38,39). 
Although there were no differences in patient characteris- 
tics and baseline troponin T concentrations between our 
treatment groups, we observed a peak in troponin T median 
values 8 and 27 h after the start of treatment in the heparin 
group but not in the hirudin groups. There was no comparable 
increase in CK activity. The data indicate that minor myocar- 
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dial cell necrosis is common after coronary angioplasty in 
patients with unstable angina, which is probably related to 
angioplasty-enhaneed n othelial injury, with activation of the 
coagulation system and platelet activation leading to throm- 
botic occlusion of smaller side branches or peripheral emboli- 
zation. Postmortem studies (4) have demonstrated that micro- 
infarctions are common in patients with unstable angina as a 
result of fissuring of an atheromatous plaque, with subsequent 
episodic embolization. In addition, an intermittent critical flow 
reduction corresponding to the degree of thrombus formation 
might contribute to myocardial cell damage. As evidenced by 
the greater activated partial thromboplastin time prolongation 
in the heparin group during the first 24 h, this difference in our 
results cannot be related to insufficient anticoagulation i  the 
heparin group. 
Our results indicate that hirudin may have greater potential 
than heparin to prevent such early ischemic events after 
coronary angioplasty for unstable angina pectoris. Moreover, a 
second peak in troponin T concentration was observed after 
27 h. Again, there was an increase in troponin T levels in the 
heparin group only. This increase may be related to a rebound 
phenomenon after cessation or reduction of the heparin dose. 
A rebound phenomenon leading to myocardial infarction or 
recurrent chest pain after stopping heparin therapy has been 
observed by Theroux et al. (40) and Granger et al. (41). Gold 
et al. (42) reported rebound thrombin generation with an early 
dose-related recurrence of unstable angina after cessation of 
brief-duration therapy (4 h) with the specific thrombin inhib- 
itor argatroban. Conversely, Topoi et al. (25) did not find a 
rebound phenomenon after stopping hirudin therapy. 
Bleeding complications. In previous trials (43,44), a trend 
toward an excess of hemorrhagic stroke was observed in 
patients receiving hirudin compared with those receiving hep- 
arin. We observed only one major bleeding event related to the 
catheter insertion site in 40 hirudin-treated patients. However, 
the number of patients in our study was too small for definite 
risk assessment of bleeding complications. 
A prolonged activated partial thromboplastin time was 
associated with an increased risk of major hemorrhage in both 
heparin- and hirudin-treated patients in the Thrombolysis in 
Myocardial Infarction 9A trial (45). These data confirm the 
findings of our study, demonstrating greater antithrombotic 
efficacy with hirudin than heparin at a lower activated partial 
thromboplastin time level. 
Conclusions. Our results support he postulated e/ficacy of 
r-hirudin in preventing myocardial ischemia after coronary 
angioplasty for unstable angina pectoris. Hirudin has the 
potential to provide more complete and potent antithrombotic 
action than heparin during and after coronary angioplasty, 
possibly at a lower activated partial thromboplastin time level 
than that required for the same antithrombotic effect of 
heparin. No safety risks, particularly in terms of bleeding, were 
manifested uring the course of the present study. 
Appendix 
Study Co-Investigators 
Mainz: C. Bickel, J. R6fig, M. Cobaugh, U. Wenderoth. Hamburg: 
M. Hoffmann, J. Jacobs, A. Cortes. Homburg: W. Bay, G. Berg, U. 
Lotze. Aachen: U. Janssens, Y. Grafen. Regensburg: M. Muscholl. 
Behringwerke: H. Heinrichs, M. Nebel, R. Miihlich, F. Schindel. 
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